Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis

Annals of the Rheumatic Diseases

Volumn 76, Issue 3, 2017, Pages 543-546

  Miloslavsky, Eli M ^a   Naden, Ray P ^b   Bijlsma, Johannes W J ^c   Brogan, Paul A ^d   Brown, E Sherwood ^e   Brunetta, Paul ^f   Buttgereit, Frank ^g   Choi, Hyon K ^h   Dicaire, Jean Francois ⁱ   Gelfand, Jeffrey M ^j   Heaney, Liam G ^k   Lightstone, Liz ^l   Lu, Na ^a   Murrell, Dedee F ^m   Petri, Michelle ⁿ   Rosenbaum, James T ^o   Saag, Kenneth S ^p   Urowitz, Murray B ^q   Winthrop, Kevin L ^o   Stone, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f GENENTECH INC   (United States)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p University of Alabama at Birmingham   (United States)

^q UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Corticosteroids; Outcomes research; Treatment

Indexed keywords

GLUCOCORTICOID;

ADRENAL INSUFFICIENCY; ARTICLE; AVASCULAR NECROSIS; CENTRAL SEROUS RETINOPATHY; CLINICAL DECISION MAKING; CORTICOSTEROID INDUCED MYOPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG USE; FRACTURE; GLUCOCORTICOID TOXICITY INDEX; HUMAN; HYPERTENSION; INTESTINE PERFORATION; INTRAOCULAR PRESSURE ABNORMALITY; MORBIDITY; MULTICRITERIA DECISION ANALYSIS; PEPTIC ULCER; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TOXICITY; SUBCAPSULAR CATARACT; TENDON RUPTURE; THRUSH; TOXICITY TESTING; TREATMENT OUTCOME; VAGINA CANDIDIASIS; CONSENSUS; CONSENSUS DEVELOPMENT; DECISION SUPPORT SYSTEM; DERMATOLOGY; INFECTIOUS DISEASE MEDICINE; INTERDISCIPLINARY COMMUNICATION; NEPHROLOGY; NEUROLOGY; OBSERVER VARIATION; OPHTHALMOLOGY; PEDIATRICS; PSYCHIATRY; PULMONOLOGY; REPRODUCIBILITY; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX;

CONSENSUS; DECISION SUPPORT TECHNIQUES; DERMATOLOGY; GLUCOCORTICOIDS; HUMANS; INFECTIOUS DISEASE MEDICINE; INTERDISCIPLINARY COMMUNICATION; NEPHROLOGY; NEUROLOGY; OBSERVER VARIATION; OPHTHALMOLOGY; PEDIATRICS; PSYCHIATRY; PULMONARY MEDICINE; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 84979687016     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210002     Document Type: Article

References (18)

1. Mcdonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008;20:131-7.
2. Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 2011;33:1413-32.
3. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
4. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371: 1189-97.
5. Fortunet C, Pers YM, Lambert J, et al. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatology (Oxford) 2015;54:672-7.
6. Van Der Goes MC, Jacobs JWG, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010;69:1913-19.
7. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
8. Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004;63:797-803.
9. Wassenberg S, Rau R, Steinfeld P, et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371-80.
10. Black S, Eskola J, Siegrist C-A, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet (London, England) 2009;374:2115-22.
11. Johnson SR, Naden RP, Fransen J, et al. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. J Clin Epidemiol 2014;67:706-14.
12. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2015;74:1789-98.
13. Nikpour M, Urowitz MB, Gladman DD. Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr Rheumatol Rep 2009;11:248-54.
14. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011;365:62-70.
15. Bell GM, Reynolds G, Isaacs JD. Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?. Nat Rev Rheumatol 2011;7:507-16.
16. United States Food and Drug Administration. Guidance for Industry Systemic Lupus Erythematosus - Developing Medical Products for Treatment.
17. Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014;53:1470-6.
18. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.